Macquarie Group
SNNA

Macquarie Group’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Macquarie Group’s Portfolio SNNA Stock Details SNNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,238
Closed -$1K – 1961
2019
Q2 		$1K Buy
+1,238
New +$1.94K ﹤0.01% 1827

Other funds holding SNNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Macquarie Group's SNNA Position: Q3 2019 in Review

Macquarie Group sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q3 2019, closing a stake of 1,238 shares — an estimated $1K sold.

Macquarie Group first reported a position in SNNA in Q2 2019 and held it in 1 quarter. The position peaked at $1K in Q2 2019. 23 funds tracked by Wall St. Rank hold SNNA as of Q3 2019.

  • Macquarie Group reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Macquarie Group sold 1,238 Sienna Biopharmaceuticals, Inc. shares in Q3 2019, an estimated $1K.
  • Macquarie Group first reported a position in Sienna Biopharmaceuticals, Inc. in Q2 2019 and held it in 1 quarter.
  • Macquarie Group's Sienna Biopharmaceuticals, Inc. position peaked at $1K in Q2 2019.
  • 23 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q3 2019.

Based on Macquarie Group's 13F filing for Q3 2019, filed 14 Nov 2019.